B-61 | Incidence of Patient Prosthesis Mismatch (PPM) After ViV-TAVI and ViV-TAVI With Bioprosthetic Valve Fracture (BVF)

Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) is an effective treatment for degenerated bioprosthetic valves in high-risk patients. Unfortunately, patient prosthesis mismatch (PPM) remains issue. PPM known to impact functional status, longevity, morbidity and mortality. Bioprosthetic fracturing (BVF) a method by which operators fracture the allowing greater expansion of new or larger valve. We sought determine incidence patients undergoing ViV-TAVI safety BVF. Patients who underwent at our institution from 2015-2022 were selected divided into two groups (with BVF without BVF). was performed discretion operator. severity assessed as insignificant, moderate severe. Moderate defined indexed orifice area (iEOA) <0.85 cm2/m2 (if BMI<30 kg/m2) <0.70 BMI>30 kg/m2). Severe iEOA <0.65 <0.55 Measurements taken TTE on post operative day 1. All-cause mortality 30-days 1-year. A total 78 ViV-TAVI, 25 had suboptimal gradients successfully treated with The mean age 76.71 years old. overall 0.69 ± 0.20 cm2/m2. present 43.4% that while only 16% 1 required permanent pacemaker group. Amongst 96.2% living 90.6% BVF, 100% 96% more often compared Short term appears be similar between complications rates are low.